A Copper Complex as Anti-Tumor Agents

</a><strong>Background</strong><br>

There is still a considerable demand for the improvement of cytotoxic cancer therapeutics regarding the toxicity and the tolerance. While platinum-based chemotherapy is the standard of care for patients with lung cancer, other metal-containing agents could not be established in the treatment of cancer diseases.<br><br> <strong>Technology</strong><br> Therefore, we offer a novel copper-based compound, displaying strong and selective anti-tumor activity in a broad range of hematological cancers and solid tumors, high efficiency against relapse, improved tolerance and reduced toxicity.<br><br> In vitro studies revealed strong apoptotic and anti-proliferative effects of metal- organic copper sarcolysin (MOC*Scr) in comparison to other cytotoxic drugs. When combined with other cytotoxic drugs, MOC*Scr showed strong synergistic effects pointing towards a different mechanism. Furthermore, MOC*Scr demonstrated potent activity in cell lines resistant to other standard drugs such as Vincristin, Daunorubicin and Doxorubicin. Additional in vivo studies revealed that the MOC*Src treatment leads to significant tumor growth reduction of 60-90% in syngenic and xenograft tumor models. Also terminal stage IV patients benefited from the treatment with MOC compound in investigator initiated trials.<br><br> Thus, these results position MOC*Scr as an exciting new cancer therapeutic agent.<br><br> <b>Benefits:</b><ul> <li>Excellent anti-tumor activity and synergistic effect with other cytotoxic drugs</li> <li>Wide spectrum of application including solid tumors and hematological cancers</li> <li>Overcomes resistances ex vivo</li> <li>Convenient oral administration</li> <li>Small molecule with short and simple synthesis</li></ul> <p><strong>IP Rights</strong><br> EP and PCT (DE, EP, AU, BR, CA, CN, IN, JP, RU, US) application filed in February 2008 and February 2009 <br><br> <strong>Patent Owner</strong><br> Technology Development Funds of Investitionsbank Berlin

Further Information: PDF

ipal GmbH
Phone: +49 (0)30/2125-4820

Contact
Dr. Dirk Dantz